...
首页> 外文期刊>Cytokine >How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response
【24h】

How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response

机译:体内细胞因子释放综合征的体外测定有多大预测性?方法的比较表明,敏感性和响应频率存在令人担忧的差异

获取原文
获取原文并翻译 | 示例
           

摘要

To the Editor, The disastrous phase I clinical trial with the CD28 superagonis-tic monoclonal antibody (mAb) TGN1412 has prompted the development and refinement of various in vitro tests to better predict the risk of serious infusion reactions, particularly cytokine release syndrome (CRS), following mAb administration to humans. However, we read the recent paper by Wolf et al. [1], describing a whole blood in vitro cytokine release assay intended for the prediction of mAb-induced CRS, with considerable concern. These authors measured concentrations of IFNy, TNFalpha, IL-2, IL-4, IL-6, IL-8 and IL-10, released in minimally diluted whole blood in response to aqueous phase mAbs which included a TGN1412-like analogue (TGN1412L), another anti-CD28 superagonistic mAb (ANC28.1), a T cell depleting mAb (Orthoclone) associated with CRS of varying severity, and a TGN1412 subclass matched mAb (Tysabri) rarely associated with CRS, and claimed that their whole blood assay is a 'suitable new method for hazard identification' in the quest for CRS-predictive tests. However, we do not consider that the data presented support this claim.
机译:致编辑,具有CD28超激动性单克隆抗体(mAb)TGN1412的灾难性I期临床试验促使开发和完善各种体外试验,以更好地预测发生严重输注反应的风险,尤其是细胞因子释放综合征(CRS) ,对人类进行mAb给药后。但是,我们阅读了Wolf等人的最新论文。 [1],描述了用于预测mAb诱导的CRS的全血体外细胞因子释放测定法,引起了广泛关注。这些作者测量了响应于水相mAb的最低稀释的全血中释放的IFNγ,TNFα,IL-2,IL-4,IL-6,IL-8和IL-10的浓度,其中水相单克隆抗体包括类似TGN1412的类似物(TGN1412L ),另一种抗CD28超激动性单克隆抗体(ANC28.1),与严重程度不同的CRS相关的T细胞耗竭单克隆抗体(Orthoclone)和与CRS很少相关的TGN1412亚类匹配的单克隆抗体(Tysabri),并声称其全血检测是寻求CRS预测性测试的“合适的危险识别新方法”。但是,我们不认为所提供的数据支持这一主张。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号